問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberMK3475-590
Completed

2017-06-01 - 2024-04-08

Phase III

Terminated9

ICD-10C16

Malignant neoplasm of stomach

ICD-10D00

Carcinoma in situ of oral cavity, esophagus and stomach

  • Trial Applicant

    Merck Sharp & Dohme (I.A.) LLC

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/04/01

Investigators and Locations

Principal Investigator Chih-Hung Hsu Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Audit

None

Principal Investigator 邱倫瑋 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Chen-Yuan Lin Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Shang-Yin Wu Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Audit

None

Principal Investigator Shau-Hsuan Li Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 林建良 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Chen-Yuan Lin 未分科

Co-Principal Investigator

Audit

None

Principal Investigator

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

2 Terminated

Audit

None

Principal Investigator Hsien-Kun Chang Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Audit

None

Principal Investigator 郭集慶 Division of Hematology & Oncology

Co-Principal Investigator

  • 柯萬盛 Division of Hematology & Oncology

The Actual Total Number of Participants Enrolled

0 Terminated

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    60 participants

  • Global

    749 participants